NYSE · Financial Statements

Boston Scientific Corporation (BSX) Financial Statements

$45.69 NYSE: BSX Market Cap $66.22B

Boston Scientific Corporation most recently reported annual revenue of $20.1B, net profit of $2.9B. Revenue grew at an average annual rate of 15.2% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Boston Scientific Corporation: Revenue rose from $8.4B in 2016 to $20.1B in 2025, a change of +139.4% over 9 years; net profit was positive in 9 of 10 reported years; operating margin moved from 14.7% to 19.8%, a shift of +5.0 percentage points; the most recent year shows net profit of $2.9B.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$8.4B$9.0B$9.8B$10.7B$9.9B$11.9B$12.7B$14.2B$16.7B$20.1B
Operating Expenses$7.2B$7.5B$8.1B$9.0B$9.3B$10.0B$10.9B$12.1B$14.1B$16.1B
Operating Profit$1.2B$1.5B$1.7B$1.7B$601.0M$1.9B$1.8B$2.2B$2.6B$4.0B
Operating Margin14.7%16.9%17.7%15.9%6.1%16.2%14.4%15.3%15.7%19.8%
Other Income$-1.1B$-592.0M$-315.0M$-1.0B$-680.0M$-846.0M$-683.0M$-196.0M$-353.0M$-586.0M
Interest$234.0M$230.0M$269.0M$513.0M$468.0M$349.0M$464.0M$272.0M$387.0M$349.0M
Depreciation$815.0M$844.0M$894.0M$1.0B$1.1B$1.1B$1.1B$1.2B$1.3B$1.4B
Profit Before Tax$177.0M$933.0M$1.4B$687.0M$-79.0M$1.1B$1.1B$2.0B$2.3B$3.4B
Tax$-96.0M$88.8M$-17.5M$-584.1M$-2.5M$3.4M$38.8M$19.8M$19.1M$14.6M
Net Profit$347.0M$104.0M$1.7B$4.7B$-82.0M$1.0B$698.0M$1.6B$1.9B$2.9B
EPS$0.25$0.07$1.19$3.33$-0.08$0.69$0.45$1.07$1.25$1.94
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$3.5B$3.7B$3.9B$4.1B$4.2B$4.6B$4.7B$5.1B$5.1B$5.3B$5.2B$5.4B
Operating Expenses$3.0B$3.2B$3.2B$3.4B$3.5B$4.0B$3.8B$4.2B$4.0B$4.1B$4.1B$4.3B
Operating Profit$558.0M$558.0M$644.0M$747.0M$674.0M$589.0M$896.0M$819.0M$1.1B$1.2B$1.1B$1.2B
Operating Margin15.8%15.0%16.7%18.1%16.0%12.9%19.2%16.2%20.7%22.8%20.6%21.6%
Interest$67.0M$67.0M$72.0M$81.0M$83.0M$139.0M$87.0M$90.0M$87.0M$90.0M$90.0M$96.0M
Profit Before Tax$609.0M$505.0M$608.0M$420.0M$668.0M$585.0M$805.0M$941.0M$939.0M$700.0M$1.2B$1.1B
Tax$17.2M$200,000$18.9M$23.3M$29.9M$3.9M$16.5M$15.5M$19.5M$4.4M$-15.2M$14.6M
Net Profit$504.0M$504.0M$494.0M$324.0M$469.0M$566.0M$674.0M$793.0M$755.0M$668.0M$1.3B$907.0M
EPS$0.34$0.34$0.33$0.22$0.32$0.38$0.45$0.53$0.50$0.45$0.90$0.61

Over the 10 years reported for Boston Scientific Corporation, borrowings increased from $5.5B in 2016 to $12.4B in 2025, cash stood at $2.0B in the latest year, shareholders' equity was $17.0M, current assets covered current liabilities 1.62 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$18.1B$19.0B$21.0B$30.6B$30.8B$32.2B$32.5B$35.1B$39.4B$43.7B
Current Assets$3.2B$3.8B$4.0B$4.7B$6.7B$6.3B$5.8B$6.5B$6.9B$8.8B
Cash$196.0M$188.0M$146.0M$217.0M$1.7B$1.9B$928.0M$865.0M$414.0M$2.0B
Inventory$955.0M$1.1B$1.2B$1.6B$1.4B$1.6B$1.9B$2.5B$2.8B$2.9B
Receivables$1.5B$1.5B$1.6B$1.8B$1.5B$1.8B$2.0B$2.2B$2.6B$2.9B
Fixed Assets$1.6B$1.7B$1.8B$2.4B$2.5B$2.7B$2.8B$3.3B$3.7B$4.5B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$-75.0M$-191.0M$-328.0M$458.0M$918.0M$412.0M$407.0M$413.0M$555.0M$842.0M
Other Assets$6.7B$7.0B$7.9B$10.2B$10.0B$12.0B$12.9B$14.4B$17.1B$18.3B
Total Liabilities$11.4B$12.0B$12.3B$16.7B$15.5B$15.6B$14.9B$15.6B$17.4B$19.2B
Current Liabilities$3.6B$5.7B$5.3B$4.9B$3.7B$4.3B$3.8B$4.9B$6.4B$5.4B
Borrowings$5.5B$5.6B$7.0B$10.3B$9.5B$9.5B$9.3B$9.5B$11.1B$12.4B
Other Liabilities$5.9B$6.5B$5.2B$6.4B$5.9B$6.2B$5.6B$6.1B$6.2B$6.8B
Equity$19.0M$16.0M$16.0M$16.0M$17.0M$17.0M$17.0M$17.0M$17.0M$17.0M
Reserves$6.7B$7.0B$8.7B$13.9B$15.3B$16.6B$17.6B$19.3B$21.8B$24.2B

For Boston Scientific Corporation, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $3.7B; free cash flow was positive in 9 of 10 years; financing activities used $186.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$972.0M$1.4B$310.0M$1.8B$1.5B$1.9B$1.5B$2.5B$3.4B$4.5B
Investing Cash Flow$-1.3B$-1.3B$-2.2B$-5.5B$-787.0M$-2.2B$-2.6B$-3.4B$-6.5B$-3.5B
Financing Cash Flow$-127.0M$-98.0M$-74.0M$56.0M$-630.0M$-150.0M$-328.0M$-145.0M$-243.0M$-186.0M
Net Cash Flow$-123.0M$530.0M$-190.0M$-222.0M$1.4B$171.0M$-1.0B$-82.0M$-449.0M$1.5B
Free Cash Flow$596.0M$1.1B$-6.0M$1.4B$1.1B$1.3B$914.0M$1.7B$2.6B$3.7B

Valuation & Return Ratios

MetricValue
PEG Ratio0.39
EV / EBITDA13.62
FCF Yield5.55%
Quick Ratio0.74
Interest Coverage12.41
Return 1Y-55.38%
Return 3Y-10.34%
Return 5Y1.58%

Boston Scientific Corporation (BSX) financials — frequently asked questions

What is Boston Scientific Corporation's annual revenue?

Boston Scientific Corporation (BSX) reported annual revenue of $20.1B in its most recent fiscal year.

What is Boston Scientific Corporation's net profit?

Boston Scientific Corporation (BSX) reported net profit of $2.9B in its most recent fiscal year.

What is BSX EV/EBITDA?

Boston Scientific Corporation's enterprise value to EBITDA (EV/EBITDA) ratio is 13.62.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
BSX Overview BSX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.